KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways

British Journal of Pharmacology

Volumn 159, Issue 5, 2010, Pages 1151-1160

  Yeh, Jwu Lai ^a   Hsu, Jong Hau ^a,b   Wu, Ping Ju ^a   Liou, Shu Fen ^c   Liu, Chung Pin ^b   Chen, Ing Jun ^a   Wu, Bin Nan ^a   Dai, Zen Kong ^a,b   Wu, Jiunn Ren ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Calcineurin A; Cardiac hypertrophy; Isoprenaline; KMUP 1; Nitric oxide

Indexed keywords

CALCINEURIN; CALCINEURIN A; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPRENALINE; KMUP 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N(G) NITROARGININE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SURVIVAL; WISTAR RAT;

ANIMALS; CALCINEURIN; CARDIOMEGALY; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FIBROSIS; ISOPROTERENOL; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PIPERIDINES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SURVIVAL RATE; XANTHINES;

EID: 77949362015     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00587.x     Document Type: Article

References (31)

1. Aaronson KD, Sackner-Bernstein J (2006). Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA 296: 1465-1466.
2. Bueno OF, Molkentin JD (2002). Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91: 776-781.
3. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R et al. (2000). The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19: 6341-6350.
4. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS (1998). Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101: 812-818.
5. 2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res 63: 450-457.
6. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F et al. (2002). Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 99: 11363-11368.
7. Frey N, Katus HA, Olson EN, Hill JA (2004). Hypertrophy of the heart: a new therapeutic target? Circulation 109: 1580-1589.
8. Hassan MA, Ketat AF (2005). Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 5: 10.
9. Ing DJ, Zang J, Dzau VJ,Webster KA, Bishopric NH (1999). Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 84: 21-33.
10. Kinugawa KI, Kohmoto O, Yao A, Serizawa T, Takahashi T (1997). Cardiac inducible nitric oxide synthase negatively modulates myocardial function in cultured rat myocytes. Am J Physiol 272: H35-H47.
11. Kishimoto I, Rossi K, Garbers DL (2001). A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 98: 2703-2706.
12. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566.
13. + channels. Br J Pharmacol 135: 1159-1166.
14. Liu CM, Lo YC, Wu BN, Wu WJ, Chou YH, Huang CH et al. (2007). cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy. Prostate 67: 1397-1410.
15. Liu CM, Lo YC, Tai MH, Wu BN, Wu WJ, Chou YH et al. (2009). Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts. Prostate 69: 610-623.
16. Loke KE, McConnell PI, Tuzman JM, Shesely EG, Smith CJ, Stackpole CJ et al. (1999). Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res 84: 840-845.
17. Molkentin JD (2004). Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63: 467-475.
18. Morisco C, Zebrowski D, Vatner DE, Vatner SF, Sadoshima J (2001). β-Adrenergic cardiac hypertrophy is mediated primarily by the β1-subtype in rat heart. J Mol Cell Cardiol 33: 561-573.
19. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T et al. (2002). Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 109: 735-743.
20. Ozaki M, Kawashima S, Yamashita T, Hirase T, Ohashi Y, Inoue N et al. (2002). Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 66: 851-856.
21. Ramos JW (2008). The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 40: 2707-2719.
22. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH (2003). Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 57: 515-522.
23. Sadoshima J, Izumo S (1997). The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59: 551-571.
24. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. (2005). Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222.
25. Wenzel S, Rohde C, Wingerning S, Roth J, Kojda G, Schluter KD (2007). Lack of endothelial nitric oxide synthase-derived nitric oxide formation favors hypertrophy in adult ventricular cardiomyocytes. Hypertension 49: 193-200.
26. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF et al. (2002). Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 22: 7603-7613.
27. + channels opening activities in rat aortic smooth muscle. Br J Pharmacol 134: 265-274.
28. + channels. Br J Pharmacol 142: 1105-1114.
29. Wu BN, Chen CW, Liou SF, Yeh JL, Chung HH, Chen IJ (2006). Inhibition of proinflammatory tumor necrosis factor-{alpha}-induced inducible nitric-oxide synthase by xanthine-based 7- [2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3- dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1, 3-dimethylxanthine (KMUP-3) in rat trachea: The involvement of soluble guanylate cyclase and protein kinase G. Mol Pharmacol 70: 977-985.
30. Wu JR, Liou SF, Lin SW, Chai CY, Dai ZK, Liang JC et al. (2009). Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 59: 48-56.
31. Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF (2003). Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem 278: 47694-47699.